Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on mast cell biology and antibody-based therapeutics for allergic, inflammatory, autoimmune and other mast cell-mediated diseases. Company updates center on barzolvolimab, a humanized monoclonal antibody being studied across chronic spontaneous urticaria, cold urticaria and symptomatic dermographism, as well as pipeline work that includes CDX-622 in asthma.
Recurring news themes include clinical data presentations at allergy and dermatology meetings, financial results, corporate updates and capital actions. Celldex also reports financing activity tied to its common stock and development priorities for its antibody-based immunology pipeline.
Celldex Therapeutics (NASDAQ:CLDX) reported significant progress in its pipeline during Q1 2020, despite COVID-19 challenges. The company completed enrollment in the Phase 1 study of its KIT inhibitor, CDX-0159, set for presentation at the EAACI Annual Congress 2020. Celldex plans to expand CDX-0159's development for chronic urticaria and is preparing for a Phase 1 study of CDX-527 in advanced cancers. Q1 2020 financials showed revenues of $2.7 million, primarily from a $1.8 million milestone payment, while net loss decreased to $12.6 million. Celldex's cash is sufficient to fund operations into Q2 2021.
Celldex Therapeutics (NASDAQ: CLDX) announced that results from the Phase 1 study of CDX-0159 will be presented as a late-breaking poster at the EAACI Annual Congress 2020, taking place digitally from June 6-8, 2020. The study shows that CDX-0159, an anti-KIT monoclonal antibody, achieves dose-dependent reductions in serum tryptase levels, indicating a favorable safety profile. Following promising results, Celldex plans to expand CDX-0159's development into Phase 1b studies for chronic spontaneous and inducible urticaria.